our company

mission statement

Santaris Pharma A/S, a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, is delivering on the promise of RNA-targeted medicines, today. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. Santaris Pharma A/S internal research and development activities currently focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies cover a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders.

vision statement

Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine capabilities, Santaris Pharma A/S aims to deliver effective and well tolerated RNA-targeted therapies that have the ability to inhibit and cure diseases and to improve the quality of life of patients with critical diseases where options are inadequate or do not exist.